Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.58M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
704K
-
Shares change
-
+501K
-
Total reported value, excl. options
-
$264K
-
Value change
-
+$188K
-
Number of buys
-
8
-
Number of sells
-
-1
-
Price
-
$0.38
Significant Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q4 2024
18 filings reported holding CYCC - Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q4 2024.
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 704K shares
of 1.58M outstanding shares and own 44.43% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (580K shares), UBS Group AG (47.3K shares), TWO SIGMA SECURITIES, LLC (28.6K shares), Point72 Asset Management, L.P. (15.3K shares), ACADIAN ASSET MANAGEMENT LLC (14.3K shares), GEODE CAPITAL MANAGEMENT, LLC (10.8K shares), Tower Research Capital LLC (TRC) (5.59K shares), SBI Securities Co., Ltd. (802 shares), Financial Gravity Companies, Inc. (200 shares), and Archer Investment Corp (200 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.